The authors have noted that the calculation of the effect estimate for i.v. antihypertensive use on acute kidney injury (AKI) and the inpatient mortality outcome was incorrect in this paper . While the numerical estimates for AKI have changed, the interpretation does not (i.v. antihypertensive use was not significantly associated with AKI). However, this is not the case for death. Whereas the authors originally reported no association between i.v. antihypertensive use and death, they now find a significant association. The overall conclusion for the study, that i.v. antihypertensive use to correct severe inpatient hypertension does not have robust clinical support stands. These changes do not affect the conclusion of the paper  or the accompanying commentary on this article .
The corrections for this paper  are as follow:
In Table 2 the Unweighted crude HR [95% CI] for Acute kidney injury (i.v. versus no treatment) should be 1.35 [1.18, 1.54] instead of 1.06 [0.93, 1.21], and for Death (i.v. versus no treatment) should be 2.07 [1.39, 3.08] instead of 1.08 [0.72, 1.60].
In Table 2 the Overlap propensity weighted HR [95% CI] for Acute kidney injury (i.v. versus no treatment) should be 1.18 [0.99, 1.40] instead of 0.97 [0.81, 1.17], and for Death (i.v. versus no treatment) should be 3.16 [1.96, 5.09] instead of 0.86 [0.49, 1.51].
In the Infographic the Overlap propensity weighted HR [95% CI] for Acute Kidney Injury should be 1.18 [0.99, 1.40] instead of 0.97 [0.81, 1.17], and for Death and should be 3.16 [1.96, 5.09] instead of 0.86 [0.49, 1.51].
The authors would also like to point out related errors to the information in the supplementary files, and these are highlighted in the supplementary file to this erratum (see Supplemental Digital Content 1, https://links.lww.com/HJH/C181).
1. Ghazi L, Li F, Simonov M, Yamamoto Y, Nugent JT, Greenberg JH, et al. Effect of intravenous antihypertensives on outcomes of severe hypertension in hospitalized patients without acute target organ damage. J Hypertens
2. van Twist DJL, Kietselaer BLJH. Intravenous antihypertensive drugs: a double-edged sword? J Hypertens